Use of D-Enantiomeric Peptide Ligands of Monomeric α-Synuclein for the Therapy of Various Synucleinopathies

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a group of specially designed D-enantiomeric peptides that specifically bind to monomeric alpha-synuclein proteins. These peptides are engineered to stabilize the native (non-aggregated) form of alpha-synuclein and prevent or reverse its pathological aggregation into oligomers and fibrils, which are hallmarks of synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The invention offers both the compositions and methods to use these peptides as potential therapeutics for these neurodegenerative diseases.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of Parkinson's disease by preventing or reducing the aggregation of alpha-synuclein.
• Therapy for dementia with Lewy bodies (DLB) associated with alpha-synuclein pathology.
• Treatment of multiple system atrophy (MSA), another synucleinopathy.
• Use as a research reagent for studying alpha-synuclein aggregation and its inhibition.
• Development of diagnostic tools or assays involving alpha-synuclein aggregation.
• Potential combination therapies with other neuroprotective agents targeting neurodegeneration.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets the underlying cause of synucleinopathies (protein misfolding/aggregation), not just symptoms.
• D-enantiomeric peptides are more resistant to enzymatic degradation, increasing their stability in vivo.
• Specific binding to monomeric alpha-synuclein helps preserve normal protein function.
• Prevents formation of toxic oligomers and aggregates, potentially halting or reversing disease progression.
• Demonstrated potential to detoxify existing aggregates, offering both preventive and therapeutic effects.
• High specificity and modifiability of peptides allow for optimization in drug development.
• Potential for fewer side effects compared to conventional small molecule drugs due to high target specificity.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7, as well as to such a peptide for using in the treatment of synucleinopathies.